BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18631016)

  • 21. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
    Al Enazi MM; Kadry R; Mitwali H
    J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 23. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 24. Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib.
    Visvardis EE; Gao F; Paes MN; Duprez O; Waxman J
    QJM; 2012 Jul; 105(7):689-92. PubMed ID: 21693543
    [No Abstract]   [Full Text] [Related]  

  • 25. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
    Rogiers A; Wolter P; Op de Beeck K; Thijs M; Decallonne B; Schöffski P
    Thyroid; 2010 Mar; 20(3):317-22. PubMed ID: 20144039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Yıldız I; Varol U; Şen F; Kılıç L
    Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
    [No Abstract]   [Full Text] [Related]  

  • 27. Sunitinib-induced pseudoporphyria.
    Sanz-Motilva V; Martorell-Calatayud A; Llombart B; Requena C; Serra-Guillén C; Nagore E; Guillén C; Traves V; Sanmartín O
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1848-50. PubMed ID: 24813651
    [No Abstract]   [Full Text] [Related]  

  • 28. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

  • 29. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 30. Sunitinib-induced thrombotic microangiopathy.
    Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
    J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
    Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
    JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
    [No Abstract]   [Full Text] [Related]  

  • 32. Sunitinib-aggravated hypertension.
    Rivera F; Benounna M; Sánchez de la Nieta MD
    J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    Kalantari HR
    Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
    [No Abstract]   [Full Text] [Related]  

  • 34. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How does sunitinib cause hypothyroidism?
    Hershman JM; Liwanpo L
    Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
    [No Abstract]   [Full Text] [Related]  

  • 36. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 37. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
    Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
    J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
    Martín G; Bellido L; Cruz JJ
    J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
    [No Abstract]   [Full Text] [Related]  

  • 39. [New drugs; sunitinib and sorafenib].
    van Bronswijk H; Dubois EA; Osanto S; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid function in psoriasis.
    Hansen PR; Isaksen JL; Jemec GB; Ellervik C; Kanters JK
    Br J Dermatol; 2019 Jul; 181(1):206-207. PubMed ID: 30629295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.